Search

Hutchison China MediTech Ltd ADR

Fechado

SetorSaúde

12.82 -2.95

Visão Geral

Variação de preço das ações

24h

Atual

Mín

12.56

Máximo

13.36

Indicadores-chave

By Trading Economics

Rendimento

-8.9M

-8M

Vendas

3.7M

139M

P/E

Médio do Setor

142.7

50.373

Margem de lucro

-5.724

Funcionários

1,790

EBITDA

18M

4M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+38.78% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

568M

2.5B

Abertura anterior

15.77

Fecho anterior

12.82

Hutchison China MediTech Ltd ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

30 de out. de 2026, 23:51 UTC

News

FMC Corp shares are declining in after-market hours following disappointing Q3 earnings, with an 80% revenue drop to $106 million and an adjusted loss per share of $4.41.

30 de out. de 2026, 23:51 UTC

News

BTIG suspended its Buy rating on Zoetis Inc, contributing to a modest decline in the stock during after-market hours.

30 de out. de 2026, 23:51 UTC

News

Stryker receives mixed analyst assessments, with Stifel lowering its price target to $325 and Citigroup adjusting to $315, both maintaining Buy ratings.

30 de out. de 2026, 23:41 UTC

News

Allegro Microsystems Inc. reported Q2 FY27 sales of $276.88M, exceeding expectations, and provided Q3 guidance of $278M to $288M, with shares modestly higher in after-market trading.

30 de out. de 2026, 23:41 UTC

News

BTIG suspended its Buy rating on IDEXX Laboratories, contributing to a decline in the stock's price during after-market hours.

30 de out. de 2026, 23:36 UTC

News

Capri Holdings Ltd reported Q2 profit of 42 cents per share and raised full-year EPS forecast to $2.20, with shares trading lower in after-market hours.

30 de out. de 2026, 23:31 UTC

News

McGrath RentCorp will replace Glaukos in the S&P 600 index at the market open on November 4, 2026, contributing to positive after-market price movement.

30 de out. de 2026, 23:26 UTC

News

JP Morgan maintains its Underweight rating on T. Rowe Price while raising the price target to $107; TD Cowen lowers its target to $96.

30 de out. de 2026, 23:26 UTC

News

Citigroup reaffirms Buy rating on Fortrea Holdings Inc and raises price target to $27, according to a report published today.

30 de out. de 2026, 23:21 UTC

News

Compass Inc. faces a class action lawsuit from Pomerantz LLP, alleging securities fraud related to its merger with Anywhere Real Estate Inc.

30 de out. de 2026, 23:16 UTC

News

JP Morgan maintains Neutral rating on Dexcom Inc and raises its price target to $85, reflecting the company's market position and growth potential.

30 de out. de 2026, 23:11 UTC

News

Pomerantz LLP has filed a class action lawsuit against The Chemours Company, alleging misleading statements and violations of federal securities laws.

30 de out. de 2026, 23:11 UTC

News

Cantor Fitzgerald identifies Binance's $6.3 billion hack as a potential buying opportunity for crypto-linked stocks, including Strategy Inc., amid recovery confidence.

30 de out. de 2026, 23:06 UTC

News

Uranium Energy Corp. shares declined in after-market hours, reflecting broader sector pressures despite analysts noting tightening supply in the uranium market.

30 de out. de 2026, 23:06 UTC

News
Social Media

S&P Global Ratings revised its outlook on Meta Platforms, Inc. to negative, citing uncertainty over capital expenditures and projected free operating cash flow deficits.

30 de out. de 2026, 23:06 UTC

News
Social Media

eBay expands managed shipping program amid seller eligibility concerns.

30 de out. de 2026, 23:06 UTC

News
Social Media

Coinbase Global, Inc. received an Overweight rating from JP Morgan, which lowered its price target to $187 amid security concerns following the $6.3 billion Binance hack.

30 de out. de 2026, 23:06 UTC

News

Starbucks plans to trial an AI-driven "fast pass" feature for drive-throughs to enhance customer experience, leveraging its app and loyalty program.

30 de out. de 2026, 23:06 UTC

News

Kraft Heinz Company shares are trading modestly higher in after-market hours, remaining above their 20-day moving average and near the upper end of their one-month range.

30 de out. de 2026, 23:06 UTC

News

The Hershey Company is trading higher in after-market hours, following analysts' adjustments with Evercore ISI lowering its price target to $200 and TD Cowen maintaining $198.

30 de out. de 2026, 23:06 UTC

News

DraftKings Inc. shares declined in after-market trading, pulling back from earlier gains as investors anticipate an upcoming earnings report amid ongoing pressure.

30 de out. de 2026, 23:06 UTC

News

Celsius Holdings faces a class action lawsuit from Pomerantz LLP over alleged federal securities law violations related to its Alani Nu energy drinks' marketing practices.

30 de out. de 2026, 23:06 UTC

News

Citigroup maintains a Neutral rating on Enphase Energy and lowers its price target to $25, which may have influenced investor sentiment.

30 de out. de 2026, 23:06 UTC

Correlated Moves
News

Ares Capital Corp announces a merger agreement to acquire MidCap Financial Investment Corporation, leading to the cancellation of MidCap's earnings call on November 5, 2026.

30 de out. de 2026, 23:02 UTC

Macro News
News

Bitcoin has declined below $77K following a significant security breach at Binance, resulting in the theft of approximately $6.3 billion and raising cybersecurity concerns.

30 de out. de 2026, 23:01 UTC

News

Dyadic International Inc will report its Q3 2026 financial results and host a conference call on November 12, 2026, to enhance investor transparency.

30 de out. de 2026, 23:01 UTC

News

Rivian Automotive reported Q3 revenue of $2.15 billion and raised full-year delivery guidance to 67k units, despite shares falling in after-market trading.

30 de out. de 2026, 23:01 UTC

News

BWX Technologies Inc. is rising in after-market trading after being selected by the U.S. Army for a $2.2 billion nuclear microreactor project.

30 de out. de 2026, 23:01 UTC

News

JP Morgan maintains Neutral rating on Republic Services and raises price target to $265, following an update published after the market close.

30 de out. de 2026, 23:01 UTC

News

Twilio Inc. is under investigation by Levi & Korsinsky for potential federal securities law violations related to its lowered Q4 revenue growth guidance.

Comparação entre Pares

Variação de preço

Hutchison China MediTech Ltd ADR Previsão

Preço-alvo

By TipRanks

38.78% parte superior

Previsão para 12 meses

Média 18.25 USD  38.78%

Máximo 18.5 USD

Mínimo 18 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

2

Comprar

0

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat